NervGen Pharma Common stock Operating Income

NervGen Pharma Common stock (NGEN) currently reports a operating income of $-38M as of June 2026. That compares with $-27M in the prior-year period — down 43.5% year over year. Use the charts on this page to explore NervGen Pharma Common stock's operating income history and peer comparisons.

NervGen Pharma Common stock's operating income decreased from $-27M to $-38M — a 43.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NervGen Pharma Common stock reported $-38M in operating income as of June 2026. That compares with $-27M in the prior-year period — down 43.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-38M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NervGen Pharma Common stock, and consider following NGEN for alerts when major investors trade the stock.

NervGen Pharma Common stock is classified in the Healthcare sector. On operating income, it currently shows $-38M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NGEN with unrelated industries.